Blog
RSS FeedPosted by Michael Wonder on 31 Mar 2020
Health economic assessment of Keytruda in combination with Inlyta in kidney cell cancer
31 March 2020 - TLV has developed a health economic knowledge base for the regions for combination treatment with the drugs ...
Posted by Michael Wonder on 23 Mar 2020
COVID-19 and processing times
23 March 2020 - At present, TLV's operations continue as usual. ...
Posted by Michael Wonder on 23 Mar 2020
Final reconciliation of savings from side agreements full year 2019
20 March 2020 - TLV has presented the final reconciliation to the government on the outcome of the reimbursements in ...
Posted by Michael Wonder on 17 Mar 2020
Erlotinib new exchange groups
13 March 2020 - As of April, erlotinib is included as an exchange group on the list of goods for ...
Posted by Michael Wonder on 16 Mar 2020
TLV has decided to reconsider subsidy restrictions for several drugs
16 March 2020 - TLV starts two different re-examination of subsidy restrictions for certain drugs and drug groups with the ...
Posted by Michael Wonder on 09 Mar 2020
Health economic assessment of Kadcyla in the treatment of HER2 positive, early breast cancer
6 March 2020 - TLV has developed a health economic knowledge base for the regions for the drug Kadcyla (trastuzumab emtansine). ...
Posted by Michael Wonder on 25 Feb 2020
TLV has decided on a policy for patient participation
21 February 2020 - TLV has taken another step in developing patient participation by developing a policy. ...
Posted by Michael Wonder on 16 Feb 2020
New and removed exchange groups
14 February 2020 - An exchange group is a group of drugs that the Swedish Medicines Agency has judged to be ...
Posted by Michael Wonder on 12 Feb 2020
Withdrawal from the drug benefits on 1 March 2020
12 February 2020 - Aprovel, Differin and Plavix are among the medicines that are withdrawn from the drug benefits at the ...
Posted by Michael Wonder on 05 Feb 2020
Mayzent is granted temporary subsidy
5 February 2020 - The Dental and Pharmaceutical Benefits Agency has decided that Mayzent, 0.25 and 2 mg film-coated tablet ...
Posted by Michael Wonder on 28 Jan 2020
TLV is reviewing the subsidy of factor VIII drugs with side agreements
28 January 2020 - Factor VIII drugs are used to treat a form of hemorrhagic disease, hemophilia A, which involves ...
Posted by Michael Wonder on 16 Jan 2020
Withdrawal from the drug benefits on 1 February 2020
16 January 2020 - Iressa, Procoralan, Skinoren Cream, Vesicare and Reyataz are among the medicines that are withdrawn from the drug ...
Posted by Michael Wonder on 15 Jan 2020
TLV has decided to reconsider the subsidy for Xeljanz
14 January 2020 - When TLV decided that Xeljanz should be included in the high-cost protection, this was justified by the ...
Posted by Michael Wonder on 15 Jan 2020
TLV has decided to reconsider the subsidy for Olumiant
14 January 2020 - When TLV decided that Olumiant should be included in the high-cost protection, this was justified by the ...
Posted by Michael Wonder on 18 Dec 2019
Health economic assessment of Kyprolis in combination with Revlimid and dexamethasone
17 December 2019 - TLV has developed a new health economic knowledge base for the regions of the drug Kyprolis ...